Previous clinical studies have established that PCSK9 inhibitors are able to reduce both LDL‐C and Lp(a).17 In addition, the PCSK9 R46L loss‐of‐function mutation is associated with reduced risk of AVS and myocardial infarction.18 Recently, experimental data suggested that PCSK9 may also directly facilitate calcification in valvular interstitial cells.19 Taken together, PCSK9 inhibition therapy could potentially reduce AVS disease progression and valve‐related events. This evidence concerns the gene PCSK9 and myocardial infarction.